

RECEIVED
CENTRAL FAX CENTER

MAR 02 2005

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Practitioner's Docket No. MPI00-079P1RCP2CN1M

PATENT

Certificate of Transmission under 37 CFR 1.8

(703) 872-9306

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on March 2, 2005


Signature

Diana Gentile

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify
each submitted paper.

Submitted herewith:

Status Inquiry

(1 page)

Total

Pages (2 pages)
(Including this cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MAR 02 2005

Practitioner's Docket No. MPI00-079P1RCP2CN1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Meyers, Rachel E., et al.
Application No.: 10/664,506 Group No.: 1652
Filed: September 17, 2003 Examiner: TBA
For: 32142, 21481, 25964, 21686, NOVEL HUMAN DEHYDROGENASE
MOLECULES AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATUS INQUIRY

Kindly inform the undersigned, attorney of record, of the status of the above-identified patent application. The last communication received by the undersigned was the Notice of Publication dated April 22, 2004. Applicants note the PAIR status indicates the application processing is complete, and the case has been docketed to the Examination Division as of March 2004.

March 2, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By Kerri Pollard Schray
Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone - (617) 551-3676
Facsimile - (617) 551-8820

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office. (703) 872-9306

Diana Gentile
SignatureDate: March 2, 2005

Diana Gentile

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 1)